UNSPSC 51181631: Dextrothyroxine sodium

This classification denotes a thyroid agent with the molecular formula C15H10I4NO4.Na.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0H00N2AHSP, chemically known as 3,3,5,5-tetraiodo-d-thyronine, sodium salt but more generally known as dextrothyroxine sodium, which bears US NIH Compound Identifier 8729. European Medicines Agency schedules Dextrothyroxine sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07055MIG.

Most nations, for tariff and trade purposes, schedule dextrothyroxine sodium under HS 29225000 and SITC 51467. As of Q4 2014, DEXTROTHYROXINE SODIUM remains US FDA's Preferred Term for this commodity. Dextrothyroxine sodium bears US NLM identifiers UMLS NCI C65373. SMILES: C1C(CC(C(C1I)OC2CC(C(C(C2)I)O)I)I)C[C@H](C(=O)[O-])N.O.[NA+].

UNSPSC 51181631 Dextrothyroxine sodium is a Commodity code covering a synthetic thyroid hormone used in cardiovascular and metabolic management. State and local procurement under this code flows primarily through cooperative purchasing agreements that bundle dextrothyroxine sodium with broader generic pharmaceutical and over-the-counter product portfolios rather than as standalone single-product solicitations. The work involves manufacturers supplying FDA-compliant products with assigned National Drug Codes (NDCs) through authorized drug wholesalers to state and local government healthcare facilities, schools, and subordinate agencies. Issuing bodies are primarily state health and human services departments and multistate cooperative purchasing alliances that aggregate demand across multiple member states and localities; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administers one of the largest active vehicles in this space, representing participating state and local entities across Minnesota, Oregon, and other member jurisdictions.

The geographic center of recent activity is the upper Midwest and Pacific Northwest, with Minnesota (through MMCAP administration) and Oregon as the identified participating states in the most recent solicitation. MMCAP issued a Request for Proposal in January 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026 and contract effectiveness of July 1, 2026. The RFP requires vendors to maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, or Morris & Dickson Co., LLC), certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and accept pricing models including flat price, net price formats, or WAC-minus structures. Evaluation weights heavily price competitiveness (75 percent) with administrative compliance, EDI capability, and fixed pricing forming the remainder. No specific award value is disclosed; vendors should anticipate a 3 percent administrative fee on purchases and performance penalties of $200 to $1,500 per violation.